Commentary: Nanoparticle-Based Chemotherapy Delivery and Potential Health Risks: Prospects for Effective Clinical Translation

• Published in: Technology in cancer research & treatment Vol. 22; p. 15330338231220171
• Main Authors: Assefa, Desta, Melaku, Tsegaye, Alemu, Sintayehu
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.01.2023; Sage Publications Ltd; SAGE Publishing
• Subjects: Cancer therapies; Chemotherapy; Drug Compounding; Drug Delivery Systems; Drug Delivery Systems for Cancer Therapeutics; Drug development; Health risk assessment; Health risks; Humans; Microenvironments; Nanomedicine; Nanoparticles; Nanotechnology; Neoplasms - drug therapy; Neoplasms - pathology; Permeability; Translation; Tumor Microenvironment; nanoparticle; clinical translation; health risks; chemotherapy
• ISSN: 1533-0346; 1533-0338
• DOI: 10.1177/15330338231220171

With recent advancements, chemotherapy is one of the most prevalent regimens for cancer treatment. However, the heterogeneity of tumor biology and healthy cell-damaging potential of chemotherapy remain challenges. As a solution, nanoparticle-based delivery is advancing. Besides its promising potential, effective clinical translation and commercialization of nanoparticle-based chemotherapy should get attention to ensure the absence of potential health risks. Specifically, the permeability potential of nanoparticles across biological barriers can lead to drug accumulation in vital organs and produce harm. Therefore, for effective design and clinical application of next-generation nanomedicine, pharmaceutical formulation scientists should conduct intensive studies. They involve studying the properties of drug-loaded nanoparticles in the microenvironment of the target site and the impact of interspecies differences using quantitative and mechanistic studies. It creates a comprehensive understanding of the specific properties of nanoparticles and their interaction potential with biological systems. This commentary justifies the requirement for comprehensive knowledge of the above-mentioned criteria and tests for the success of nanomedicine for chemotherapy delivery.